A BIOMARKER-DRIVEN PROTOCOL FOR PREVIOUSLY TREATED ALKPOSITIVE NON-SQUAMOUS NSCLC PATIENTS: THE NCI-NRG ALK PROTOCOL
Breast cancer treatment and diagnosis
Primary Objective • To assess whether ALK kinase domain mutations (G1202/C1156Y /I1171/L1196/ V1180/ F1174/ compound mutation) associated with drug resistance are prognostic for objective response to subsequent ALK inhibitor therapy. • To assess whether subsequent pemetrexed based chemotherapy improves objective response comparing to ALK inhibitor therapy for no ALK mutation patients • To evaluate objective responses of patients with specific genetic alterations (ALKL1198F/MET double mutation or high-level MET gene amplification) treated with crizotinib.
Dr. Mohammad Jahanzeb
MD, FACP, FASCO
Medical OncologistWorks at 2 centers.
Dr. Edgardo Santos
Medical OncologistAventura (Medical oncology)
Warning: count(): Parameter must be an array or an object that implements Countable in /var/www/html/wp-content/themes/genesiscare/src/components/hcp_clinical_trial_heading/hcp_clinical_trial_heading.php on line 299
Warning: Invalid argument supplied for foreach() in /var/www/html/wp-content/themes/genesiscare/src/components/hcp_clinical_trial_heading/hcp_clinical_trial_heading.php on line 301